Barbara Melosky

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 396 citations · Full text

Medicine, Oncology, Pharmacology +17

Management of Skin Rash during egfr-Targeted Monoclonal Antibody Treatment for Gastrointestinal Malignancies: Canadian Recommendations

Barbara Melosky, Ronald L. Burkes, Daniel Rayson et al. · Current Oncology · 2009 · 138 citations · Full text

Medicine, Dermatology, Oncology +17

Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Induced Skin Toxicities in Patients With Metastatic Lung Cancer

Barbara Melosky, Helén Anderson, Ronald L. Burkes et al. · Journal of Clinical Oncology · 2015 · 95 citations

Medicine, Oncology, Pharmacology +16

Treatment of AIDS-Related Cutaneous Kaposi's Sarcoma With Topical Alitretinoin (9-cis-Retinoic Acid) Gel

Sharon Walmsley, Donald W. Northfelt, Barbara Melosky et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 1999 · 88 citations

Medicine, Dermatology, Pharmacotherapy +14

Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin

Sharlene Gill, Barbara Melosky, L Haley et al. · The American Journal of Medicine · 2003 · 80 citations

Medicine, Oncology, Pathology +13